Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland

This study involved a post-hoc analysis exploring the clinical and patient-reported benefits of proactive versus reactive management with Cal/BD foam observed in the PSO-LONG trial (NCT02899962). A range of response criteria based on mPASI and DLQI were analyzed, and the cost-effectiveness of proactive versus reactive management was estimated in a Finnish healthcare setting.Results and conclusion: The analysis found a consistent clinical benefit of proactive management compared to reactive management on all response criteria, and a markedly lower cost per responder for the response criteria of mPASI 75, mPASI ≤2 and DLQ1 ≤ 1. The analysis was robust to sensitivity analyses on key inputs and demonstrates the cost and clinical benefits of proactive over reactive management of plaque psoriasis with Cal/BD foam in the Finnish healthcare setting.PMID:34130573 | DOI:10.1080/09546634.2021.1942419
Source: Journal of Dermatological Treatment - Category: Dermatology Authors: Source Type: research